Choosing between hims and skinny.rx for weight loss involves weighing full clinical support and platform maturity against aggressive budget pricing. hims operates as an established multi-category telehealth leader serving over 2 million patients since 2017, providing GLP-1 medications through board-certified obesity medicine physicians with platform technology and integration across erectile dysfunction, hair loss, and mental health services. skinny.rx launched in 2023 as an ultra-budget GLP-1 specialist offering the lowest-cost access to compounded semaglutide and tirzepatide through a streamlined prescribing model. This comparison examines treatment options, pricing differences, clinical support quality, platform capabilities, and service breadth to help you determine which approach aligns with your weight loss goals, budget constraints, and healthcare preferences.
Platform Overview
hims launched in 2017 as one of the first direct-to-consumer telehealth platforms, growing to serve over 2 million customers across multiple health categories including weight loss, erectile dysfunction, hair loss, mental health, and premature ejaculation. The platform operates through a network of licensed healthcare providers offering FDA-approved medications with optional subscription models. hims has established itself as a mainstream telehealth leader with service offerings, board-certified physicians, and HIPAA-compliant systems serving all 50 states.
skinny.rx launched in 2023 as a budget-focused weight loss telehealth platform specializing exclusively in GLP-1 medications for obesity treatment. The platform positions itself as an ultra-affordable alternative to established providers, offering semaglutide and tirzepatide through a streamlined consultation process. skinny.rx operates with a narrow focus on weight loss medications only, targeting price-sensitive patients seeking the lowest-cost access to GLP-1 therapy through a simplified service model with a bare-bones telemedicine setup, according to
FDA semaglutide safety information.
Weight Loss Treatment Options
hims Weight Loss Approach: hims offers GLP-1 medication access including both semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) through board-certified obesity medicine physicians. The platform provides FDA-approved medications with standard dosing protocols following clinical guidelines from the
American Association of Clinical Endocrinology. hims includes medication management with ongoing provider consultation, prescription adjustments based on response and tolerability, and coordination with pharmacies for medication fulfillment. The weight loss program operates as an integrated service within hims broader telehealth platform.
skinny.rx Medication Focus: skinny.rx specializes exclusively in compounded semaglutide and tirzepatide formulations, offering only GLP-1 medications without additional treatment options. The platform does not name the compounding pharmacy that fills its prescriptions or the tier it operates under, though its compounded GLP-1s cost less than brand-name drugs. skinny.rx follows standard dosing escalation protocols but offers limited medication management beyond initial prescription. The platform focuses on medication access rather than full obesity treatment, with minimal lifestyle intervention or ongoing clinical support beyond prescription refills.
Clinical Efficacy: Both platforms provide medications with established weight loss efficacy. According to FDA Wegovy prescribing information, semaglutide 2.4mg produced average weight loss of 14.9% body weight over 68 weeks in the STEP 1 trial (individual results vary).
FDA Zepbound label reports average weight loss of 15% to 20.9% depending on dose in the 72-week SURMOUNT-1 trial (individual results vary). Both platforms provide access to these evidence-based medications, though hims offers branded and generic options while skinny.rx focuses exclusively on compounded formulations at lower price points.
Pricing and Value Comparison
hims Pricing Structure: hims weight loss medication runs $149-299/month and every option on its page is FDA-approved: oral Wegovy $149, the Wegovy pen $199, Zepbound $299, with Ozempic and Mounjaro listed far higher at $1,899. On top of that sits a required Weight Loss Membership, $39 the first month and $149/month after, billed separately and excluding medication. The honest ongoing floor is therefore $298/month, close to $3,576 a year, and there is no separate $49 consultation fee in the current structure (checked on hims.com, September 12, 2026). hims runs weight loss as a cash-pay service and accepts HSA/FSA.
skinny.rx Budget Pricing: skinny.rx positions itself as the lowest-cost provider in the GLP-1 market, with monthly medication costs ranging from $149-249/month for compounded semaglutide and $199-299/month for compounded tirzepatide. The platform charges a $25 initial consultation fee, significantly lower than most competitors. skinny.rx operates exclusively as a cash-pay service without insurance billing, focusing on transparent pricing for uninsured patients. Annual costs range from $1,788-3,588, representing approximately 25-40% savings compared to hims for equivalent medications.
Value Assessment: For patients seeking the absolute lowest price for GLP-1 medications, skinny.rx undercuts hims by a wider margin than the sticker prices suggest, because the hims membership adds $149/month to whatever the medication costs. What hims gives back is FDA-approved product across the whole menu, fuller clinical support, and integration with a broader telehealth platform serving multiple health needs.
Medical Team and Clinical Support
hims Clinical Team: hims operates with a network of board-certified physicians and obesity medicine specialists licensed in all 50 states. The platform employs physicians with specific training in obesity medicine and experience managing GLP-1 medications. hims provides asynchronous telemedicine consultations through secure messaging, with typical response times of 24-48 hours for clinical questions. The platform offers ongoing medication management including dose adjustments, side effect management, and coordination of care with patients primary care providers when needed.
skinny.rx Lean Clinical Model: skinny.rx operates with a streamlined provider network offering basic telemedicine consultations for GLP-1 prescriptions. The platform employs licensed healthcare providers but does not specify board certification in obesity medicine or training. Clinical consultations are primarily asynchronous with limited ongoing support beyond prescription refills. skinny.rx focuses on medication access rather than full weight management, with little capacity for handling complex medical questions or coordinating care with other providers.
Support Quality Differences: hims provides substantially more strong clinical support with experienced obesity medicine physicians, complete medication management, and established protocols for handling adverse events and treatment complications. skinny.rx offers basic prescribing services adequate for straightforward cases but lacks the clinical depth for patients with complex medical histories or those experiencing significant side effects. JAMA research on telemedicine quality emphasizes the importance of qualified provider networks and comprehensive clinical support for chronic disease management, factors favoring hims more established medical infrastructure.
Platform Features and User Experience
hims Platform Capabilities: hims provides a full-featured telehealth platform with mobile apps for iOS and Android, secure messaging with providers, prescription management tools, and medication tracking features. The platform offers automated refill reminders, shipment tracking, and integrated payment processing. hims has invested heavily in user experience design, creating an intuitive interface with educational resources about weight loss medications, side effect management guidance, and lifestyle modification support. The platform integrates weight loss services with hims broader health offerings, allowing patients to address multiple health concerns through a single account, according to
FDA GLP-1 safety warnings.
skinny.rx, Kept Minimal: skinny.rx operates with a simplified platform focused exclusively on weight loss medication ordering. The service provides basic consultation questionnaires, prescription processing, and medication shipping but lacks the sophisticated features of more established platforms. skinny.rx does not offer mobile apps, automated refill systems, or integrated health tracking tools. The platform prioritizes simplicity and cost reduction over feature richness, appealing to patients who value affordability over technological sophistication.
Technology Gap: hims provides significantly more advanced platform capabilities including mobile accessibility, tracking tools, and seamless integration across multiple health categories. skinny.rx offers adequate functionality for basic medication ordering but cannot match the user experience refinement of a mature platform with years of development investment. For patients who value convenience, technology integration, digital health tools, hims represents a substantially more sophisticated option despite higher costs.
Treatment Scope and Service Breadth
hims Multi-Category Platform: hims serves patients across weight loss, erectile dysfunction (sildenafil, tadalafil), hair loss (finasteride, minoxidil, dutasteride), mental health (sertraline, escitalopram, bupropion), and premature ejaculation (sertraline, paroxetine). This breadth allows patients to address multiple health concerns through a single platform, with coordinated care across conditions. For patients with co-occurring issues common in metabolic syndrome - such as obesity, erectile dysfunction, and depression - hims integrated approach provides management through one provider network. The platform formulary includes dozens of medications across these categories.
skinny.rx Single-Focus Service: skinny.rx exclusively provides weight loss medications, with no services for other health conditions. This narrow focus allows the platform to optimize for cost efficiency in GLP-1 delivery but limits utility for patients with multiple health needs. Patients requiring treatment for conditions beyond weight loss must use separate telehealth platforms, managing multiple accounts, provider relationships, and payment systems. skinny.rx does not offer the integrated care approach possible with multi-category platforms.
Service Scope Implications: For patients needing only weight loss medication at minimum cost, skinny.rx focused model aligns well with their needs. However, many weight loss patients have related health concerns including erectile dysfunction, depression, and metabolic conditions. hims ability to address these interconnected issues through one platform provides significant convenience and potentially better coordinated care compared to skinny.rx single-condition focus.
Same Price, Different Medication Menu
Hims and Skinny.Rx both list weight loss at $199/mo as of August 2026, a genuine tie on price, with Hims rated 9.4 Outstanding and Skinny.Rx 9.0 Excellent.
The menus differ: Skinny.Rx's own listing breaks out compounded injectable semaglutide from $149.25/mo and compounded tirzepatide tablets from $224.25/mo alongside FDA-approved Wegovy, while Hims' own listing highlights name-brand, FDA-approved GLP-1 options at no price markup.
The compounded semaglutide and tirzepatide here are on the Skinny.Rx side, and they are not FDA-approved or reviewed by the FDA for safety, effectiveness, or quality. Hims' weight loss page lists no compounded option at all, so confirm which version you would actually be prescribed before you compare price.
How We Compared Hims vs Skinny.Rx
Our Comparison Methodology
This comparison is based on comprehensive analysis of clinical protocols, pricing structures, medical team qualifications, platform capabilities, and service models from both hims and skinny.rx.
Clinical Evidence: Weight loss treatment recommendations reference FDA-approved GLP-1 medication labels including Wegovy (semaglutide) and Zepbound (tirzepatide) and treatment protocols from the Obesity Medicine Association. Information on clinical efficacy, dosing protocols, and safety monitoring reflects established medical evidence for GLP-1 therapies in obesity management.
Pricing Analysis: Pricing reflects the rates last recorded in our provider database; providers change prices frequently, so confirm current pricing directly at checkout. Cost comparisons calculated for typical treatment courses to provide accurate annual expense estimates for uninsured cash-pay patients.
Service Verification: Platform capabilities, medical team credentials, medication formularies, and service scope evaluated through platform documentation, provider licensing verification, and user interface review. Assessment includes technology features, clinical support availability, and company histories.
Independence: This comparison is our own editorial work (most providers listed here pay ManyTreatments a commission when you buy through a link on this page; none pays for a placement, a rating, or a listing, and we make no claim that commissions have never influenced anything, since that is our own conduct and we cannot evidence it) and aims to provide evidence-based analysis helping patients choose appropriate weight loss telehealth services based on their clinical needs, budget constraints, and service preferences.
Final Verdict: Hims vs Skinny.Rx
Choose hims if: You value an established platform with a proven track record and financial stability for long-term chronic medication management. You want clinical support from board-certified obesity medicine physicians with strong medication management and side effect handling capabilities. You appreciate platform technology including mobile apps, automated refills, and integrated health tracking tools. You have or may develop other health needs (erectile dysfunction, hair loss, mental health) that could benefit from integrated multi-category care through one platform. You prefer the confidence of an established telehealth leader with multiple years of multi-category operating experience.
Choose skinny.rx if: You are primarily motivated by minimizing cost and need the absolute lowest price for GLP-1 medications, with potential annual savings of $600-1,200 compared to hims. You have straightforward medical history without complications requiring physician consultation or ongoing clinical management. You need exclusively weight loss medication without other health services, and single-focus platform adequately meets your needs. You are comfortable with a newer platform offering basic telemedicine without sophisticated technology features. You prioritize immediate cost savings over platform maturity and long-term certainty.
Bottom line: hims and skinny.rx represent different value propositions in weight loss telehealth - hims offers clinical support, a long track record, multi-category integration, and platform technology at higher cost ($199-399/month), while skinny.rx provides bare-bones medication access at budget pricing ($149-299/month) for price-sensitive patients with straightforward needs. For patients with medical complexity, multiple health concerns, or who value long-term platform stability and a strong clinical team, hims higher costs deliver meaningful additional value through experienced physicians, complete support systems, and proven reliability. For straightforward cases where lowest medication cost is the primary consideration and patients are comfortable with basic prescribing services from a newer platform, skinny.rx significant price advantage (25-40% savings) may outweigh hims additional features. The choice depends on whether you prioritize care and certainty (hims) or maximum cost reduction (skinny.rx) for your weight loss treatment journey.
Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards
